Ryvu Therapeutics S.A.

Equities

RVU

PLSELVT00013

Biotechnology & Medical Research

Market Closed - Warsaw S.E. Other stock markets 09:25:46 07/06/2024 pm IST			5-day change	1st Jan Change
53.3 ^PLN	-1.30%		-1.30%	-7.30%

17/05	Transcript : Ryvu Therapeutics S.A. - Special Call
13/03	Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Ryvu Therapeutics S.A. Appoints Hendrik Nogai to the Role of Chief Medical Officer

March 15, 2022 at 03:42 pm IST

Ryvu Therapeutics S.A. announced that Hendrik Nogai, M.D. is appointed to the role of Chief Medical Officer. Dr. Nogai brings 10 years of practice in the treatment of hematological and solid tumor malignancies and 17 years of industry experience in clinical development. Dr. Nogai will lead medical, clinical, and regulatory functions to support and guide the development of the company's pipeline.

Latest news about Ryvu Therapeutics S.A.

Transcript : Ryvu Therapeutics S.A. - Special Call	17/05
Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03	CI
Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting	06/03	CI
Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS	14/02	CI
Ryvu Therapeutics Announces Dosing of the First Patient in the River-81 Phase Ii Study of Rvu120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory Aml	31/01	CI
Transcript : Ryvu Therapeutics S.A. - Special Call	11/12
Ryvu Therapeutics S.A. Presents Data on Rvu120 At the San Antonio Breast Cancer Symposium 2023	07/12	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11	CI
Transcript : Ryvu Therapeutics S.A. - Special Call	23/23/23
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120	23/23/23	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	13/23/13	CI
Ryvu and TIM to enter Warsaw's mWIG40 index	31/23/31	RE
Ryvu Therapeutics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24	CI
Ryvu Therapeutics S.A. Presents Clinical and Translational Data of RVU120 and SEL24 at the 2022 American Society of Hematology Annual Meeting	11/22/11	CI
BioNTech Forms Multi-Target Research Collaboration With Ryvu Therapeutics	30/22/30	MT
BioNTech to Make $21 Million Equity Investment in Ryvu Therapeutics	30/22/30	MT
BioNTech SE and Ryvu Therapeutics S.A. Enters into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates	30/22/30	CI
Ryvu Therapeutics S.A. announced that it expects to receive ?20 million in funding from BioNTech SE	30/22/30	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	23/22/23	CI
Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 at the 2022 American Society of Hematology Annual Meeting	03/22/03	CI
Ryvu Therapeutics S.A. Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium	26/22/26	CI
Ryvu Therapeutics S.A. announced that it expects to receive PLN 1.899998 million in funding	06/22/06	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	28/22/28	CI
Poland's Ryvu Therapeutics Bags $22 Million EU Financing To Develop New Cancer Drugs	17/22/17	MT

Chart Ryvu Therapeutics S.A.

Duration

Period

More charts

Company Profile

Ryvu Therapeutics SA, formerly known as Selvita SA, is a Poland-based company engaged in the healthcare industry. The Company is active in the pharmaceutical and biotechnology fields. It operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Companyâs portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. It operates through unit Ardigen SA and SORS Holdings Ltd.

Sector

Biotechnology & Medical Research

Calendar

14/06/2024 - European Hematology Association Meeting - Abstract No 6466

More about the company

Income Statement Evolution

More financial data

Ratings for Ryvu Therapeutics S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

53.3 PLN

Average target price

70.83 PLN

Spread / Average Target

+32.90%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RYVU THERAPEUTICS S.A.	-7.30%	31Cr
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	12TCr
REGENERON PHARMACEUTICALS, INC.	+14.19%	11TCr
BIONTECH SE	-4.93%	2.42TCr
ARGENX SE	+3.23%	2.28TCr
GENMAB A/S	-10.44%	1.8TCr
WUXI APPTEC CO., LTD.	-41.74%	1.64TCr
BEIGENE, LTD.	-13.31%	1.64TCr
NEUROCRINE BIOSCIENCES, INC.	+2.44%	1.36TCr
SAREPTA THERAPEUTICS, INC.	+27.89%	1.17TCr

Bio Therapeutic Drugs